Commercial Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales BioSpaceAnalysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk's Wegovy pill.Metabolic & GLP-1Read full story pharminent May 6, 2026 (Last updated: May 7, 2026) BioSpace Analysts and investors alike had been eagerly awaiting sales figures for Novo Nordisk’s Wegovy pill. Metabolic & GLP-1 Read full story Post navigation Previous: CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026Next: FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
